Roche, Alnylam’s zilebesiran succeeds in another PhII hypertension test
Alnylam Pharmaceuticals’ RNAi therapy reduced blood pressure in a Phase II hypertension test, marking its second clinical success since Roche secured a deal for the drug.
The KARDIA-2 trial studied zilebesiran versus placebo when added to one of three standard-of-care blood pressure medications in 672 adults with mild-to-moderate hypertension.
The treatment met the primary endpoint, significantly reducing 24-hour mean systolic blood pressure at three months compared with placebo in each of the three standard-of-care settings, according to Alnylam’s release. Zilebesiran, which targets angiotensinogen (AGT), also demonstrated an “encouraging” safety profile, the company said. AGT is the most upstream precursor in the RAAS cascade, which helps regulate blood pressure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
